Samsung Biologics logo. /Courtesy of News1 On the 11th ... established in 2011 through a joint venture with Biogen, during the preparation and public announcement of the financial statements from 2012 ...

Biogen Inc. closed 46.82% short of its 52-week high of $238.00, which the company achieved on July 12th.

This was the stock's third consecutive day of losses.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. The research pact—inked with recently ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs. City Therapeutics will develop its namesake cityRNAs—short for cleavage ...

Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging tissue-enhanced delivery technologies, the partnership will concentrate on one ...

Biogen recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the past month.

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology from ...

Biogen Inc. (NASDAQ:BIIB), a prominent player in the biopharmaceutical industry specializing in neuroscience and rare diseases, finds itself at a critical juncture. According to InvestingPro ...

Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will ...

OKLAHOMA CITY — As Game 1 of the NBA Finals began at Paycom Center, discerning fans on social media asked: “Why aren’t there NBA Finals logos on the court?” For the most part – there are ...